| 摘要: |
| 目的:观察干扰素α-1b对传染性单核细胞增多症患儿EB病毒复制及免疫功能的影响。方法:选择2013年1月至2016年1月陕西省汉中市人民医院儿科收治的80例传染性单核细胞增多症患儿作为研究对象,将患儿随机分为观察组和对照组各40例,其中观察组患儿给予干扰素α-1b+更昔洛韦治疗,对照组患儿仅给予更昔洛韦治疗,选取同一时期的健康儿童40例作为空白组,比较三组患儿外周血淋巴细胞亚群分布的变化,比较观察组和对照组患儿的EB病毒DNA(EBV-DNA)转阴率、治疗有效率和不良反应发生率。结果:治疗7 d后,所有患儿CD3+和CD8+水平显著降低(P<0.05),CD4+水平和CD4+/CD8+显著升高(P<0.05)。观察组及对照组治疗后CD3+、CD8+及CD4+水平和CD4+/CD8+比较差异有统计学意义(P<0.05),治疗7 d后EBV-DNA转阴率比较差异有统计学意义(P<0.05)。显效率观察组为77.5%(31/40),对照组为55.0%(22/40),差异有统计学意义(P<0.05)。不良反应发生率观察组为10.0%(4/40),对照组为5.0%(2/40),差异无统计学意义(P>0.05)。结论:干扰素α-1b能够改善传染性单核细胞增多症患儿的细胞免疫功能,抑制EB病毒复制。 |
| 关键词: 传染性单核细胞增多症 EB病毒 细胞免疫 干扰素α-lb 更昔洛韦 |
| DOI：doi: 10.13407/j.cnki.jpp.1672-108X.2017.11.007 |
|
| 基金项目: |
|
| Interferon α-lb on Epstein-Barr Virus Replication and Cellular Immunity in Children with Infectious Mononucleosis |
| Cui Qianghua, Sun Li, Wu Lin |
| (Hanzhong People's Hospital of Shaanxi, Shaanxi Hanzhong 723000, China) |
| Abstract: |
| Objective: To study the influence of interferon α-lb on Epstein-barr virus (EBV) replication and cellular immunity in children with infectious mononucleosis. Methods: From January 2013 to January 2016, eighty children with infectious mononucleosis were chosen as study objects. All children were divided into 2 groups randomly: forty in study group (interferon α-1b+ganciclovir) and forty in control group (ganciclovir). At the same time, forty healthy children were chosen as blank group. The change of peripheral
blood lymphocyte subsets were compared among 3 groups. The negative conversion ratio of EBV-DNA, effect rate and incidence of side reactions were compared between study group and control group. Results: After treatment in 7 d, the levels of CD3+ and CD8+ decreased significantly in two groups, while the levels of CD4+ and CD4+/CD8+ increased significantly (P<0.05). These indexes demonstrated significant difference between study group and control group after 7 d (P<0.05). The negative conversion ratio of EBV-DNA had significant difference between study group and control group at 7 d after treatment (P<0.05). The marked improvement rate of study group was 77.5% (31/40), that of control group was 55.0% (22/40), the difference had statistical significance (P<0.05). The incidence of side reactions in study group was 10.0% (4/40), that in control group was 5.0% (2/40), the difference had no statistical significance (P>0.05). Conclusion: Interferon α-lb could ameliorate the cellular immunity in children with infectious mononucleosis and inhibit the EBV replication. |
| Key words: infectious mononucleosis Epstein鄄barr virus cellar immunity interferon α-1b ganciclovir |
